Irbesartan E Idroclorotiazide Eg (Hydrochlorothiazide, Irbesartan)

Irbesartan/Hydrochlorothiazide is used to manage hypertension, acting on the renin‑angiotensin‑aldosterone system and renal sodium handling.

• Essential hypertension: lowers systolic and diastolic blood pressure, reducing cardiovascular risk.
• Secondary hypertension: assists in blood pressure control when underlying causes are present.
• Hypertension with fluid retention: promotes diuresis to decrease blood volume and improve pressure control.

• Irbesartan selectively blocks angiotensin II type 1 (AT1) receptors, preventing vasoconstriction and aldosterone‑mediated sodium retention. Hydrochlorothiazide inhibits the NaCl‑Cl⁻ cotransporter in the distal convoluted tubule, reducing sodium and water reabsorption, which increases urine output and lowers plasma volume. The combined actions produce additive blood‑pressure‑lowering effects by decreasing peripheral resistance and circulating fluid volume.

Irbesartan/HCTZ may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects

• Dizziness: sensation of light‑headedness, especially after standing.
• Headache: mild to moderate intensity.
• Fatigue: general tiredness or lack of energy.
• Increased urination: due to diuretic effect.
• Electrolyte imbalance (low potassium): may cause muscle cramps.
• Dry mouth: reduced salivation.

Serious or Rare Side Effects

• Severe allergic reaction (anaphylaxis): swelling, rash, difficulty breathing.
• Acute kidney injury: sudden decrease in renal function.
• Significant hypotension: marked drop in blood pressure causing faintness.
• Hyperkalemia: high potassium levels, especially with potassium‑sparing agents.
• Pancreatitis: abdominal pain with elevated enzymes.
• Blood dyscrasias (e.g., agranulocytosis): low white blood cell counts.

When prescribing Irbesartan/HCTZ, clinicians should consider several precautionary measures to ensure safe use.

• Renal function: assess baseline kidney function and monitor periodically.
• Electrolyte levels: check serum potassium and sodium before initiation and during therapy.
• Pregnancy: avoid use unless benefits outweigh risks, as safety is not established.
• Elderly patients: start at lower dose and monitor for orthostatic hypotension.
• Concomitant NSAIDs: use cautiously as they may reduce antihypertensive effect and impair renal function.
• Store at ambient temperature: keep below 25 °C in the original container, protect from moisture and light.

Irbesartan/HCTZ can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid)

• Aliskiren: combined use may increase risk of renal impairment and hyperkalemia.
• Potassium‑sparing diuretics (e.g., spironolactone): may cause dangerous hyperkalemia.
• Lithium: increased lithium levels leading to toxicity.

Moderate Interactions (Monitor Closely)

• ACE inhibitors or other ARBs: additive blood‑pressure effect and potential renal dysfunction.
• NSAIDs: may blunt antihypertensive response and affect kidney function.
• CYP3A4 inhibitors (e.g., ketoconazole): may raise irbesartan plasma concentrations.